Population-based cohort studies have also shown that use of certain antidiabetic drugs (glitazones, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase inhibitors), associate with a lower risk of developing PD (Brakedal et al., 2017; Brauer et al., 2020; Cullinane et al., 2022). Here, GLP1R is linked to Parkinson disease.